---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-006599"
form_type: "8-K"
ticker: "BMRN"
cik: "0001048477"
company_name: "BIOMARIN PHARMACEUTICAL INC"
filed_at: "2024-01-11T23:59:59+00:00"
generated_at: "2026-06-07T00:21:20.166650+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# BioMarin CCO Jeffrey Ajer to step down effective July 1, 2024

## Summary
- Jeffrey Ajer, EVP and Chief Commercial Officer, will depart on July 1, 2024.
- No successor named; compensation unchanged until departure date.
- Separation treated as without-cause termination; Ajer eligible for severance per employment agreement.

## SEC filing metadata
- accession: 0001193125-24-006599
- form_type: 8-K
- ticker: BMRN
- cik: 0001048477
- company_name: BIOMARIN PHARMACEUTICAL INC
- filed_at: 2024-01-11T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1048477/000119312524006599/0001193125-24-006599-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1048477/000119312524006599/d719423d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-006599
- JSON: https://secwatch.observer/filing/0001193125-24-006599.json
- Plain text: https://secwatch.observer/filing/0001193125-24-006599.txt

## Key facts
- Executive change
  Jeffrey Ajer departed as Executive Vice President and Chief Commercial Officer at BIOMARIN PHARMACEUTICAL INC.
  - Action: step down
  - Role: Executive Vice President and Chief Commercial Officer
  source text: On January 11, 2024, BioMarin Pharmaceutical Inc. (“BioMarin” or the “Company”) announced that Mr. Jeffrey Ajer would step down as the Company’s Executive Vice President and Chief Commercial Officer, effective July 1, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1048477/000119312524006599/0001193125-24-006599-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.